Search jobs 26-Jan-2021
BRAIN TUMOUR:
Karl Landsteiner University of Health Sciences in Krems has identified physiological processes that indicate the recurrence of malignant brain tumours six months before clinical diagnosis.
Krems (Austria), 26th January 2021 – Lack of oxygen and specific changes in the microvascular architecture are previously undetected and very early indications of the return of a brain tumour following previous surgical intervention. This was the result of a study published by an Austrian and German team headed by Karl Landsteiner University of Health Sciences in Krems. The findings showed that initial signs of a recurrence of glioblastomas could be detected more than six months earlier than otherwise possible using standard clinical methods. Published in Clinical Cancer Research, the study was based on retrospective analysis of special MRI data from 56 patients.
Share this article
Share this article
PHILADELPHIA, Jan. 26, 2021 /PRNewswire/ Imvax, Inc., an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma Multiforme (GBM), today announced publication of Phase 1b clinical trial results in
Clinical Cancer Research, a journal of the American Association for Cancer Research. The article Phase1b Clinical Trial of IGV-001 for patients with Newly Diagnosed Glioblastoma is available online.
IGV-001 is a first-in-class personalized immunotherapy that uses the patient s own tumor cells combined with an antisense molecule to induce a potent immune response. The treatment comprises irradiated autologous glioma cells with an antisense oligodeoxynucleotide directed at the IGF-1R (Insulin-like Growth Factor type one Receptor) named IMV-001. Delivered through an implantable and removable bio-diffusion chamber, antigenic products are released and initiate both an innate and adaptive response.
Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.
CEACAM7 : Novel protein may improve safety of therapy for pancreatic cancer
This is an exciting development, said John Marshall, Professor from Queen Mary University of London
Saturday January 23, 2021 12:45 PM, IANS
London: Researchers have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.
Using this protein as a target, the team successfully created a CAR T cell therapy a type of immunotherapy that killed pancreatic cancer cells in a pre-clinical model. This is an exciting development, said John Marshall, Professor from Queen Mary University of London. Finding that CEACAM7 allows us to kill pancreatic cancer cells specifically with CAR T cells while having no significant toxicity in non-tumour tissues, gives us hope that this strategy could be effective in the future, Marshall added.
LONDON
Researchers have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer.
Using this protein as a target, the team successfully created a C